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1. Introduction 
The emergence of clinical infection due to methicillin resistant Staphylococcus aureus (MRSA) 
with decreased susceptibility to vancomycin and the frequent isolations in some countries of 
multidrug-resistant (resistant to three or more classes of antimicrobials), extensively drug 
resistant (resistant to all but one or two classes) or even pandrug-resistant (resistant to all 
available classes) Gram negative nosocomial pathogens are causing great concern 
worldwide. In an era of increasing antimicrobial resistance many recent studies have 
focused on the heteroresistance phenomenon that is considered to be a precursor stage, 
which may or may not lead to the emergence of a resistant strain. 
The term heteroresistance has been mostly used to describe hetero-vancomycin intermediate 
Staphylococcus aureus (hVISA) that spontaneously produces VISA cells within its cell 
population at a frequency of 10-6 or above (Neoh et al., 2008). In a broader sense though, 
heteroresistance may be understood as mixed populations of drug-resistant and drug-
sensitive cells in a single clinical specimen or isolate where the proportion of resistant 
organisms may not be explicable by the natural “background” mutation rate alone (Rinder, 
2001); and even more precisely, heteroresistance can be defined as resistance to certain 
antibiotics expressed by a subset of a microbial population that is generally considered to be 
susceptible to these antibiotics according to traditional in-vitro susceptibility testing (Falagas 
et al., 2008). The frequency of these resistant organisms is about one sub-clone in every 105–
106 colonies, which roughly equals the normal rate of mutation. 
2. Heteroresistance in Staphylococcus aureus 
S. aureus is the species in which the phenomenon has been reported more often and studied 
more in detail. Heteroresistance to methicillin (Ryffel et al., 1994) and oxacillin (Cimolai et 
al., 1997; H. Liu et al., 1990; Wannet, 2002) is dependent on the mecA gene that codes for a 
lower-affinity penicillin-binding protein conferring strain-specific variable resistance from 
borderline to elevated resistance to beta-lactam antibiotics. It has been shown that in 
addition to this resistance, chromosomal mutations not related to mecA may generate a small 
proportion of highly methicillin-resistant subclones (Strandén et al., 1996). 
The first reports of VISA (Hiramatsu et al., 1997a) and hVISA (Hiramatsu et al., 1997b) were 
made from Japanese hospitals in 1997 and inspired further research because vancomycin has 
been the drug of choice for infections due to MRSA. Mu 3 was the first MRSA strain 
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heteroresistant to vancomycin and it is used since then as a control strain in different 
methodologies for the detection of vancomycin heteroresistance in MRSA. Several later studies 
from various parts of the world (Borg et al., 2005; Chesneau et al., 2000; Howe et al., 1999; M.N. 
Kim et al., 2002; Marchese et al., 2000; Reverdy et al., 2001; Wang et al., 2004) have proved that 
heteroresistance to vancomycin among MRSA was maybe ignored or underestimated but not 
absent. Furthermore, since early VISA isolates in the USA were resistant to teicoplanin too 
(Appelbaum, 2007), and reduced susceptibility (Park et al., 2000) or heterogeneous resistance 
(Nunes et al., 2007) to this drug were also reported, the term glycopeptide-intermediate S. 
aureus (GISA) has been added to indicate a broader resistance profile. 
Reduced vancomycin susceptibility of hVISA and VISA strains is not linked to the vanA gene, 
which causes the high-level vancomycin resistance of certain enterococcal species and has been 
found rarely in vancomycin-resistant MRSA (VRSA) (Cui et al., 2006; Howden et al., 2008) but 
is rather a consequence of several phenotypic changes (Rong & Leonard, 2010). Among those 
suggested, the thickened bacterial cell wall is the most frequently observed (Kim et al., 2000). 
This cell wall change could probably explain also the cross-heteroresistance between 
vancomycin and daptomycin- a relatively large molecule that has to access relevant binding 
regions on the bacterial cell membrane in order to act (Sakoulas et al., 2006). 
3. Heteroresistance among Gram negative nosocomial pathogens 
Carbapenems are the most effective antimicrobial agents against Gram negative bacteria. 
Furthermore, they are stable to the hydrolytic activity of extended spectrum beta-lactamases 
and therefore they have been used widely for treating infections caused by multidrug resistant 
isolates. The extended use however of these compounds has led to the emergence of 
carbapenem resistance mechanisms mainly in members of the Enterobacteriaceae family, in 
Pseudomonas aeruginosa and Acinetobacter baumanii. Carbapenem heteroresistance among A. 
baumanii strains has been reported in a preliminary (Pournaras et al., 2005) and a complete 
study (Ikonomidis et al., 2009) from Greece where Pournaras et al. found also meropenem 
heteroresistant subpopulations in six apparently meropenem-susceptible, carbapenemase 
(KPC)-producing Klebsiella pneumoniae (KPC-KP) clinical isolates (Pournaras et al., 2010). 
Colistin is among the last-resort therapy for treating infections caused by carbapenem 
resistant pathogens but resistance to this drug is emerging in multidrug-resistant Gram 
negative bacteria (Kontopoulou et al., 2010). Heteroresistance to colistin was initially 
described among clinical A. baumannii (Li et al., 2006; C.H. Tan et al., 2007; Yau et al., 2009) 
and Enterobacter cloacae isolates (Lo-Ten-Foe et al., 2007). Intrestingly, in A. baumannii, this 
heteroresistance was documented to be related to previous colistin therapy (Hawley et al., 
2008). Heteroresistance to colistin has been reported in K. pneumoniae isolates collected from 
16 medical centers in various countries (Poudial et al., 2008) and among carbapenemase-
producing K. pneumoniae (KPC or VIM-1) regardless prior colistin therapy in a Greek 
hospital where resistant rates to colistin in carbapenemase-producing K. pneumoniae rose 
from 0% in 2007 to 24.3% in 2009 (Meletis et al., 2011). 
4. Heteroresistance in other species 
Heteroresistance to glycopeptides is not limited in S. aureus but has been described for 
Enterococcus faecium (Alam et al., 2001; Qu et al., 2009) and coagulase-negative staphylococci 
as well, including S. epidermidis, S. auricularis, S. capitis, S. haemolyticus, S. simulans and S. 
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warneri (Nunes et al., 2006; Wong et al., 1999). Heteroresistance to penicillin has been 
reported in Streptococcus pneumoniae (Morand & Muhlemann, 2007), heteroresistance to 
fluconazole and other azoles in Cryptococcus neoformans (Mondon et al., 1999; Yamazumi et 
al., 2003) while metronidazole heteroresistance in Gardnerella vaginalis has been blamed for 
therapeutic failures (Altrichter et al., 1994). 
The heteroresistance phenomenon is present even in clinical tuberculosis. It is not rare and 
not restricted to a particular resistance gene, but is obscured by cultivation as well as by 
some, culture-independent resistance prediction tests (Rinder et al., 2001). In fact, 
heteroresistant subpopulations are frequent in Mycobacterium tuberculosis although they 
seem to be well hidden. This observation may be explained by studies showing that 
acquisition of resistance results in an- at least temporary- decrease in growth rate (Billington 
et al., 1999; Gillespie et al., 2001). 
It will be very interesting to find out if heteroresistance exists even among other species or 
concerns more antimicrobial agents. It is conceivable that there is more to be found and 
further research may provide new insight in this field. 
5. Detection methods 
Detection of heteroresistance is difficult and labor-intensive. Disc diffusion method or 
commercial automated systems may fail to detect most heteroresistant isolates (Lo-Ten-Foe 
et al., 2007; Tenover, 1999), and E-test results depend on the medium used (T.Y. Tan & Ng., 
2007). Gradient plates, Disc-agar Method, E-test GRD (Glycopeptide Resistance Detection), 
Vancomycin-containig plates and E-test Macrodilution have all been explored for the 
detection of hGISA and GISA staphylococci but Population Analyses Profiles remains to 
date the most reliable method to detect heteroresistant subpopulations in Gram positive as 
well as in Gram negative bacteria. Growth of resistant subcolonies within a clear E-test 
inhibition zone and Population Screening Plates can be used for screening purposes, 
therefore, these two techniques are also described in this chapter. 
Various studies used Population Analysis Profiles-Area Under the Curve (PAP-AUC) 
(Wooton et al., 2001) as the gold standard in order to evaluate the sensitivity and 
specificity of some of the other methods. Walsh et al. evaluated seven methods in 2001 
among which, E-test Macrodilution appeared to perform better (sensitivity 96%, 
specificity 97%) for the detection of Staphylococcus strains with reduced susceptibilities to 
vancomycin (SRSV) (a term that contains both GISA and hGISA) (Walsh et al., 2001). In 
2007, Wootton et al. performed a large-scale multicenter study involving 3 different 
methods of GISA and hGISA detection (brain-heart infusion agar with 6 mg/L 
vancomycin (BHIA6V), Mueller-Hinton agar with 5 mg/L teicoplanin (MHA5T), and E-
test Macrodilution. Among them, BHIA6V had a very low sensitivity for hGISA (11.47%) 
whereas MHA5T and E-test Macrodilution performed both well. MHA5T though, gave 
twice as many false-positive results compared to E-test Macrodilution which moreover, 
resulted in significantly less variation between laboratories (Wooton et al., 2007). In 2011, 
Satola et al. evaluated the E-test Macrodilution method, E-test GRD and BHI screen agar 
plates containing 4 mg/L vancomycin and 16 g/L casein using 0.5 and 2.0 McFarland 
inocula. E-test Macrodilution was 57% sensitive and 96% specific, E-test GRD was 57% 
sensitive and 97% specific, and BHI screen agar was 90% sensitive and 95% specific with a 
0.5 McFarland inoculum and 100% sensitive and 68% specific with a 2.0 McFarland 
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inoculums (Satola et al., 2011). In the same year, van Hal et al. screened 458 MRSA 
bloodstream isolates to determine the most accurate testing strategy to detect the presence 
of heteroresistance. Compared to PAP-AUC, the sensitivities and specificities of E-test 
Macrodilution, E-test GRD, vancomycin broth microdilution (using a MIC cutoff of ≥ 2 
mg/L), and standard vancomycin E-test (using a MIC cutoff of ≥ 2 mg/L) were 89 and 
55%, 71 and 94%, 82 and 97%, and 71 and 94%, respectively (van Hal et al., 2011). 
Research for the most effective method to detect SRSV is still going on but reports of 
heteroresistance even among other clinically important species worldwide highlight the 
need for the development of a reliable and easy-to-use susceptibility testing method that can 
be used in the everyday laboratory practice. 
5.1 Population analysis profiles 
Step 1: Prepare agar plates containing varied antibiotic concentrations, for example 0, 0.5, 1, 
2, 3, 4, 5, 6, 8… mg/L. 
Step 2: Culture bacteria overnight in tryptone soya broth (TSB). 
Step 3: Prepare a cell suspension of approximately 108 CFU/ml (OD 0.3 at 578 nm or 2:3 
dilution of a 0.5 McFarland suspension). 
Step 4: Make 10-fold serial dilutions of the cell suspension and spread 50μl from each 
dilution onto a complete series of antibiotic-containing plates. (Fig. 1) 
 
Fig. 1. Meletis, G 2011, 'Population analysis profiles method', in possession of the author. 
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Step 5: Incubate at 35-37 oC for 48h. 
Step 6: Count the number of colonies grown on each plate (Table 1). 
  Drug concentration (mg/L) 
  0,5 1 2 3 4 5 6 8 
 
108         
107         
106         
105         
104         
103         
102         
Table 1. Colony counting table. 
Step 7: Plot the colony counts on a semi-logarithmic graph with colony counts on the 
vertical axis and drug concentration on the horizontal axis (Fig 2). 
Step 8: Calculate the frequency of resistant subpopulations at the highest drug concentration 
by dividing the number of colonies grown on an antibiotic containing plate by the colony 
counts from the same bacterial inoculum plated onto antibiotic-free plates. 
Step 9: Determine the MIC of the resistant subpopulations and reassess it after serial daily 
subcultures on antibiotic-free medium for 7-14 days in order to evaluate whether the 
resistance is stable. 
  
    Drug concentration (mg/L) 
Fig. 2. Colony counts plotting of eight K. pneumoniae strains tested for heteroresistance to 
colistin on a semi-logarithmic graph. Strains 4, 5 and 7 are resistant. 
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5.2 Modified population analysis profiles-AUC (area under the curve) 
Modified PAP-AUC was proposed by Wooton et al. for the detection of heteroresistance to 
vancomycin among S. aureus strains and is considered to date the gold standard for hGISA 
detection (Wooton et al., 2001). It is based upon the calculation of the ratio of the test strain’s 
AUC divided by the corresponding Mu 3 AUC. After 24h incubation in TSB, cultures are 
diluted in saline to 10-3 and 10-6 and plated onto BHIA plates containing 0.5, 1, 2, 2.5 and 4 
mg/L vancomycin. Colonies are counted after 48h incubation at 37 oC and the viable count 
is plotted against vancomycin concentration. The AUC of the study strain and Mu 3 are 
calculated and their ratio is evaluated as follows: <0.9, GSSA; 0.9-1.29, hGISA; ≥ 1.3, GISA 
(Wooton et al., 2005). 
5.3 Gradient plates 
Step 1: Culture Mu 3 and test strains overnight in TSB. 
Step 2: Pour 25 ml of BHIA containing 4 mg/L vancomycin in a 10 cm square Petri dish at 
an angle of 12o and keep solidified for 30 min in room temperature (Fig. 3). 
Step 3: Overlay 25 ml of BHIA and leave to set horizontally. Keep the solidified agar at room 
temperature for 120 min. 
Step 4: Adjust each culture to a turbidity equal to 0.5 McFarland and streak the Mu 3 and 
test strains onto the gradient agar plate with a cotton swab. 
Step 5: Measure the growth distance of the bacteria after 48h incubation at 37 oC and divide 
it with the distance grown by Mu 3 on the same plate. A ratio of ≥ 1 denotes an hGISA 
(Wooton et al., 2001). 
 
Fig. 3. Meletis, G 2011, 'Gradient plates preparation and inoculation', in possession of the 
author. 
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5.4 E-test macrodilution 
Bolmström et al. proposed that the use of a dense inoculum, rich medium and a 48h 
incubation period can optimize the detection of VISA and hVISA (Bolmström et al., 1999). 
Step 1: Spread 250 μl of a 2 McFarland suspension onto BHI agar plates and put one 
vancomycin and one teicoplanin E-test for each strain (Fig. 4). 
Step 2: Incubate at 35-37 oC for 48h. 
Step 3: Interpretation (hVISA when vancomycin MIC and teicoplanin MIC ≥ 8 or when 
teicoplanin MIC ≥ 12 and vancomycin MIC <4). 
 
 
Fig. 4. E-test Macrodilution. Photo courtesy of Dr. Tzampaz Egki. 
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5.5 Disc-agar method 
The disc-agar method has been used to demonstrate both the presence of potential 
intermediate vancomycin resistant staphylococci and staphylococci with heteroresistance to 
vancomycin on the same plate. It is based upon the observation that beta-lactam antibiotics 
(Aritaka et al., 2001; Y.S. Kim et al., 2003) and higher salinity can induce the phenotypic 
expression of vancomycin resistance and for this purpose aztreonam is preferred over other 
beta-lactam antibiotics because it has no inhibitory effect on Gram positive bacteria (Fig. 5).  
Wong et al. performed a preliminary study of the disc-agar method using different beta-
lactams including penicillins, oxacillin, cephalosporin and carbapenems. Although 
sometimes sattelitism could be seen around other beta-lactam discs, the results were less 
consistent than they were with aztreonam, and some strains had a large zone of inhibition 
around the disc (Wong et al., 1999). 
 
Fig. 5. Bacterial growth around aztreonam disc. Photo courtesy of Dr. Tzampaz Egki. 
Step 1: Prepare vancomycin-salt agar plates by incorporating 4 mg/L vancomycin and 4% 
NaCl into MHA. 
Step 2: Make a 1 McFarland bacterial suspension. 
Step 3: Inoculate with a sterile cotton swab and place a 30 μg aztreonam disc 5 minutes 
afterwards. 
Step 4: Incubate at 37 oC for 48h. 
Step 5: Suspect heteroresistance if bacterial growth is observed around the disc. The colonies 
may be homogeneous or heterogeneous in size (Fig. 6). 
Note: In any case further testing by population analysis profiles is recommended for the 
characterization of the strain’s resistance profile. 
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Fig. 6. Different size colonies around aztreonam disc. Photo courtesy of Dr. Tzampaz Egki. 
5.6 E-test GRD (glycopeptide resistance detection) 
The E-test GRD strip consists of a double-sided gradient of vancomycin and teicoplanin on a 
calibrated plastic strip. This double-sided predetermined gradient of vancomycin and 
teicoplanin is used exclusively for the detection of GISA or hGISA phenotypes. 
Strains that give a positive E-test GRD result (vancomycin or teicoplanin ≥ 8) should be send to 
a reference laboratory for further investigation by population analysis profiles (Fig. 7 and 8). 
Note: The endpoints read from the E-test GRD strips should not be regarded as true MICs, 
but rather as modified results with interpretive cutoffs defined for the phenotypic detection 
of glycopeptides resistance phenotypes in S. aureus (Yusof et al., 2007). 
Step 1: Determine the MIC of the study strain. 
Step 2: Use standard inoculum (0.5 McFarland) onto Mueller Hinton + 5% blood agar plates 
and add the GRD strip. Ensure that the whole length of the strip is in complete contact with 
the agar surface. If necessary, remove air pockets by pressing gently on the strip with 
forceps, always moving from the lowest concentration upwards. Small bubbles under the 
strip will not affect the results. 
Note: Once applied, the strip cannot be moved because the antibiotic is instantaneously 
released into the agar. 
Step 3: Incubation at 35-37 oC for 24 and 48h. 
Step 4: Results interpretation according to manufacturer’s instructions (GISA: positive E-test 
GRD and vancomycin MIC ≥ 4 mg/L, hGISA: positive E-test GRD and vancomycin MIC < 4 
mg/L). When mutant colonies are present in the inhibition eclipse, read the result where 
these colonies are completely inhibited.  
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Note: Although the procedure is straightforward, proper use of the test requires the judgment 
of skilled personnel trained in microbiology and antimicrobial susceptibility testing. 
 
Fig. 7. Negative E-test GRD. Photo courtesy of Dr. Tzampaz Egki. 
 
Fig. 8. Positive E-test GRD. Photo courtesy of Dr. Tzampaz Egki. 
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5.7 Standard E-test 
The presence of resistant subcolonies within a clear inhibition zone (Fig. 9) can potentially 
indicate for a heteroresistant isolate and in such cases, population analysis profiles is 
suggested. 
 
 
Fig. 9. Subpopulations grown within the inhibition zone. Photo courtesy of Dr. Tzampaz Egki. 
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5.8 Population screening plates 
Screening for potential vancomycin resistance can be performed using BHIA plates with 4 
mg/L vancomycin. 10 μl of a bacterial suspension from an overnight culture adjusted to 0.5 
McFarland standard is spread on the plate and bacterial growth after incubation at 37 oC for 24 
and 48h is observed. Growth at 24h may be deemed to be of the GISA phenotype and growth 
occurring between 24 and 48h may be deemed to be an hGISA strain (Walsh et al., 2001). 
6. Conclusion 
Many studies have tried to associate hGISA with failure of vancomycin therapy but this is 
still up for debate as results are controversial (van Hal & Paterson, 2011; C. Liu & 
Chambers., 2003; Neoh et al., 2007; Rong & Leonard, 2010). A further research problem is 
that such studies are difficult to perform because of the serious nature and high mortality 
rate among patients infected by MRSA. 
 
Fig. 10. Meletis, G 2011, 'Natural evolution to drug resistance due to heteroresistance', in 
possession of the author. 
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However, heteroresistance could very possibly be a tool for natural evolution to drug 
resistance, since it provides bacteria with an opportunity to explore the possibility of growth 
in the presence of antibiotics (Morand & Muhlemann, 2007). The resistant subpopulations 
may proliferate readily in the absence of competition by the inhibited susceptible cells, 
thereby giving rise to a new resistant population (Falagas et al., 2008). On the other hand, 
the emergence of resistant strains in vitro may not necessarily have therapeutic implications 
(Johnson, 1998) mainly because acquisition of resistance in some cases may be accompanied 
by loss of virulence (Fig. 10). 
Nevertheless, heteroresistant strains have been deemed to be responsible for treatment 
failures (Moore et al., 2003; Wong et al., 1999) and difficulties to detect heteroresistant 
isolates could already be contributing to a hidden spread of these strains within hospital 
facilities (Falagas et al., 2008). Therefore, more research is needed to determine the true 
clinical impact of heteroresistance and its role in the development of fully-resistant bacterial 
populations. 
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